In a preclinical model of papillary renal cell carcinomas harbouring NF2 loss25, inhibition of the YAP1 partner YES1 by dasatinib or saracatinib led to repression of Hippo transcriptional targets and provided potent antitumour activity. This evidence concerns the gene NF2 and papillary renal cell carcinoma.